iNova’s strong range of products originate from Riker Laboratories and 3M Pharmaceuticals. The business was first formed in November 2006 as the result of the purchase of 3M’s Asia Pacific and Africa pharmaceutical and OTC business. In the years since then the business has more than doubled in size through a combination of organic growth, business development and acquisitions.
In October 2017 the iNova business was sold by Valeant Pharmaceuticals International to a company jointly owned by Pacific Equity Partners (PEP) and The Carlyle Group. This presents another exciting period for iNova with both private equity owners being committed to investing further in the business to:
- support expansion into Asia, via a hub in Singapore, as well as other international regions
- continue to grow its foundational business in South Africa and Australasia
- acquire and license new products
iNova is constantly seeking innovative new prescription and consumer healthcare medicines through strong partnerships with our licensors, and Our Business Development team welcomes licensing and co-marketing proposals.